Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling

被引:11
|
作者
Luo, Yuan-Deng [1 ]
Liu, Xiao-Yu [2 ]
Fang, Lei [1 ]
Yu, Hong-Qiang [1 ]
Zhang, Yu-Jun [1 ]
Chen, Min [1 ]
Zhang, Lei-Da [1 ]
Xie, Chuan-Ming [1 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Inst Hepatobil Surg, Key Lab Hepatobil & Pancreat Surg, Chongqing, Peoples R China
[2] Southern Univ Sci & Technol, Sch Med, Shenzhen, Peoples R China
来源
THERANOSTICS | 2022年 / 12卷 / 18期
关键词
Kras; Mek; Erk; PEG3; hepatocellular carcinoma; STAT3; Cancer therapy; EVEROLIMUS; SORAFENIB; PATHWAY; SUBSET; MUTATIONS; BEHAVIOR; DEFINE; GROWTH; TRIAL; HCC;
D O I
10.7150/thno.76873
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background & Aims: Abnormal activation of mTOR through loss of tuberous sclerosis complex (Tsc) frequently occurs in hepatocellular carcinoma (HCC). Mutant Kras could induce aggressive HCCs. Here, we aim to identify the predictive or prognostic biomarkers for HCC patients with Kras mutant and mTOR hyperactivation, and to provide potential therapeutic approaches for this subtype of HCCs.Methods: We generated transgenic mice in which hepatocytic mTOR was hyperactivated through Tsc1 insufficiency with or without oncogenic KrasG12D. Bioinformatics and gain-or loss-of-function studies were used to illustrate the mechanisms underlying oncogenic pathway alterations. Transcriptional profiling was used to identify biomarker for the subtype of HCC. The therapeutic efficacy of targeting mTOR was tested in a liver orthotropic homogeneous murine model.Results: Oncogenic KrasG12D facilitated mTOR activation via the Mek/Erk/ROS axis, leading to HCC tumorigenesis and metastasis. Inhibition of Mek/Erk enhanced the anticancer effect of mTOR inhibitor via reduction of mTOR activity. Paternally expressed 3 (PEG3) was responsible for Kras/Erk-and mTOR-driven HCC. Elevated PEG3 protein interacted with STAT3 and promoted its transcriptional activity, resulting in the upregulation of proliferation-and metastasis-related proteins. Targeting mTOR significantly inhibited these actions in vitro and in vivo. Moreover, in clinical samples, PEG3 was identified as a new poor prognostic marker for HCC patients with Kras/Erk and mTOR hyperactivation.Conclusion: These findings reveal the underlying mechanism of hepatocytic Kras/Erk-driven mTOR activation and its downstream targets (PEG3 and STAT3) in HCC, identify PEG3 as a new prognostic biomarker for HCC with Kras/Erk and mTOR hyperactivation, and provide a potential therapeutic strategy for this subset of HCC patients.
引用
收藏
页码:7903 / 7919
页数:17
相关论文
共 50 条
  • [21] CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway
    Zhongwei Zhao
    Jingjing Song
    Bufu Tang
    Shiji Fang
    Dengke Zhang
    Liyun Zheng
    Fazong Wu
    Yang Gao
    Chunmiao Chen
    Xianghua Hu
    Qiaoyou Weng
    Yang Yang
    Jianfei Tu
    Jiansong Ji
    Journal of Experimental & Clinical Cancer Research, 39
  • [22] CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway
    Zhao, Zhongwei
    Song, Jingjing
    Tang, Bufu
    Fang, Shiji
    Zhang, Dengke
    Zheng, Liyun
    Wu, Fazong
    Gao, Yang
    Chen, Chunmiao
    Hu, Xianghua
    Weng, Qiaoyou
    Yang, Yang
    Tu, Jianfei
    Ji, Jiansong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [23] 3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma
    Mohan, Chakrabhavi Dhananjaya
    Yang, Min Hee
    Rangappa, Shobith
    Chinnathambi, Arunachalam
    Alharbi, Sulaiman Ali
    Alahmadi, Tahani Awad
    Deivasigamani, Amudha
    Hui, Kam Man
    Sethi, Gautam
    Rangappa, Kanchugarakoppal S.
    Ahn, Kwang Seok
    BIOLOGY-BASEL, 2022, 11 (01):
  • [24] STAT3 and β-Catenin Signaling Pathway May Affect GSK-3β Expression in Hepatocellular Carcinoma
    Wang, Xin-Hong
    Meng, Xiang-Wei
    Xing, Hui
    Qu, Bo
    Han, Ming-Zi
    Chen, Jing
    Fan, Yu-Jing
    Lu, Cheng-Qian
    Lu, Zhi-Wu
    HEPATO-GASTROENTEROLOGY, 2011, 58 (106) : 487 - 491
  • [25] STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma
    Ma, Ming
    Zhou, Yunhe
    Sun, Ruilin
    Shi, Jiahao
    Tan, Yutong
    Yang, Hua
    Zhang, Mengjie
    Shen, Ruling
    Xu, Leon
    Wang, Zhugang
    Fei, Jian
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (10) : 1063 - 1070
  • [26] Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma
    Liu, Tianshu
    Ma, Haiyan
    Shi, Wei
    Duan, Jialin
    Wang, Yina
    Zhang, Cuntai
    Li, Chenglong
    Lin, Jiayuh
    Li, Sheng
    Lv, Jiagao
    Lin, Li
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (02) : 555 - 562
  • [27] Convallatoxin promotes apoptosis and inhibits proliferation through crosstalk between JAK2/STAT3(T705) and mTOR/STAT3(S727) signaling pathways
    ZHANG Zhi-hong
    LI Ming-yue
    WANG Zhe
    JIN Hong-lan
    MA Juan
    JIN Xue-jun
    中国药理学与毒理学杂志, 2019, (10) : 893 - 894
  • [28] Curcumin Inhibits the Growth of Hepatocellular Carcinoma via the MARCH1-mediated Modulation of JAK2/STAT3 Signaling
    Su, Jiaqi
    Liu, Xianbing
    Zhao, Xiaoyue
    Ma, Hongjie
    Jiang, Yuzhu
    Wang, Xu
    Wang, Peiyuan
    Zhao, Mingdong
    Hu, Xuemei
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2024,
  • [29] Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway
    Wang, Chengzhi
    Zhou, Xiaoqing
    Xu, Hongjuan
    Shi, Xiaqing
    Zhao, Jinfeng
    Yang, Manyi
    Zhang, Lihua
    Jin, Xin
    Hu, Yu
    Li, Xia
    Xiao, Xiangcheng
    Liao, Mingmei
    JOURNAL OF CANCER, 2018, 9 (22): : 4150 - 4155
  • [30] BILE SALTS REDUCE THE CHEMOSENSITIVITY OF HEPATOCELLULAR CARCINOMA CELLS BY THE PROMOTION OF SURVIVAL AND PROLIFERATION VIA THE STAT3 SIGNALING PATHWAY
    Wang, C. Z.
    Shi, X. Q.
    Liao, M. M.
    Zhao, J. F.
    Yang, M. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 3 - 3